Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies

Clinical Lymphoma, Myeloma & Leukemia
Talha BadarGautam Borthakur

Abstract

Rat sarcoma (RAS)/rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase activation (mutational or nonmutational) is a key pathway for survival and proliferative advantage of leukemic cells. Salirasib (Concordia Pharmaceuticals) is an oral RAS inhibitor that causes dislocation of RAS by competing directly with farnesylated RAS in binding to its putative membrane-binding proteins. Salirasib does not inhibit farnesyl transferase enzyme. We report on a phase I study of Salirasib in patients with relapsed/refractory hematologic malignancies. Salirasib was administered orally twice daily on days 1 to 21 of a 28-day cycle in a "3+3" dose escalation design. Seventeen patients with relapsed/refractory leukemia were treated for a median of 4 cycles (range, 1-29). Three patients each were enrolled at a dose level of 100, 200, 400, 600, and 800 mg twice daily and 2 patients at a dose level of 900 mg twice daily. No dose-limiting toxicities were encountered. Grade 1/2 diarrhea was the only frequent nonhematologic toxicity observed in 14 of 17 (82%) patients and was resolved with oral antidiarrheal agents. Eight (47%) patients (4 with myelodysplastic syndrome, 2 with acute myeloid leukemia, 1 with chronic myelomonocytic leu...Continue Reading

References

Sep 22, 1995·The Journal of Biological Chemistry·M MaromY Kloog
Mar 1, 1994·Cancer Metastasis Reviews·R Khosravi-Far, C J Der
May 30, 1997·The Journal of Biological Chemistry·D B WhyteJ K Pai
Aug 8, 1997·Biochimica Et Biophysica Acta·A D Cox, C J Der
Nov 26, 1999·Proceedings of the National Academy of Sciences of the United States of America·B JansenK Wolff
Dec 11, 1999·Biochimica Et Biophysica Acta·G EladY Kloog
Jun 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M CrulJ H M Schellens
Jan 2, 2003·Nature Reviews. Cancer·Julian Downward
May 8, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Fadlo R KhuriWaun Ki Hong
May 4, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thomas IllmerMarkus Schaich
Jun 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Vali PapadimitrakopoulouFadlo Khuri
Jan 26, 2006·Blood·Ulrike BacherSusanne Schnittger
Jan 29, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Razelle KurzrockSaid M Sebti
Jun 2, 2009·Cancer Chemotherapy and Pharmacology·Apostolia Maria TsimberidouRazelle Kurzrock
Aug 19, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Gregory J RielyMichelle S Ginsberg
Dec 19, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kevin B KimKarl D Lewis
Nov 5, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Simone M GoldingerUNKNOWN Dermatology Cooperative Oncology Group (DeCOG)

❮ Previous
Next ❯

Citations

Sep 27, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Robert N Mahon, Richard Hafner
Sep 7, 2016·Frontiers in Oncology·Hanae SatoKeisuke Ito
Aug 30, 2016·Expert Opinion on Drug Discovery·Magdalena WitkowskaTadeusz Robak
Aug 2, 2019·Biological & Pharmaceutical Bulletin·Yoshihiko ShibayamaKen Iseki
Sep 3, 2019·Current Topics in Medicinal Chemistry·Fengqian ChenQi Liu
Sep 3, 2019·Current Topics in Medicinal Chemistry·Na YeJia Zhou
Aug 24, 2017·Journal of Experimental & Clinical Cancer Research : CR·Liwei LangYong Teng
Jun 15, 2018·International Journal of Oncology·Satoshi SugitaMasayuki Nakagawa
Jul 12, 2018·Cancer Chemotherapy and Pharmacology·Junji FuruseKazuhiko Nakagawa

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.